Prognosis of Patients Taking Selective Serotonin Reuptake Inhibitors Before Coronary Artery Bypass Grafting

Glen Xiong, Wei Jiang, Robert Clare, Linda K. Shaw, Peter K. Smith, Kenneth W. Mahaffey, Christopher M. O'Connor, K. Ranga R Krishnan, L. Kristin Newby

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Depression is increasingly recognized as an independent prognostic risk factor in patients with coronary artery disease and coronary artery bypass grafting (CABG). The use of selective serotonin reuptake inhibitors (SSRIs) for depression in patients with cardiac disease is becoming more prevalent. We examined the long-term outcomes of patients on SSRIs before CABG. We prospectively examined collected data in the Duke Databank for Cardiovascular Disease from January 1, 1999 to December 31, 2003. The median and maximum follow-up periods were 3 and 6 years, respectively. We screened patients who underwent CABG (n = 5,364) and excluded those who underwent simultaneous CABG and valvular surgery (n = 570). SSRI antidepressants included fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, and clomipramine, and their use was determined from the inpatient pharmacy records during the index hospitalization. Outcomes included event-free survival from all-cause mortality, rehospitalization, and a composite end point of all-cause mortality or rehospitalization. Of 4,794 CABG-only patients, 246 (5.1%) took SSRIs before CABG. The SSRI group had a higher prevalence of diabetes, hypercholesterolemia, hypertension, cerebrovascular disease, peripheral vascular disease, and previous cardiovascular intervention. After adjustment for baseline differences, patients on SSRIs before CABG had increased risks of mortality, rehospitalization, and the composite end point (hazard ratio 1.61, 95% confidence interval 1.17 to 2.21, p = 0.003; hazard ratio 1.52, 95% confidence interval 1.30 to 1.77, p <0.0001; and hazard ratio 1.46, 95% confidence interval 1.26 to 1.70, p <0.0001, respectively). In conclusion, SSRI use before CABG was associated with a higher risk of long-term post-CABG mortality and rehospitalization. The explanation behind these findings requires further research.

Original languageEnglish (US)
Pages (from-to)42-47
Number of pages6
JournalAmerican Journal of Cardiology
Volume98
Issue number1
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Serotonin Uptake Inhibitors
Coronary Artery Bypass
Citalopram
Mortality
Confidence Intervals
Fluvoxamine
Cerebrovascular Disorders
Sertraline
Clomipramine
Paroxetine
Peripheral Vascular Diseases
Fluoxetine
Hypercholesterolemia
Antidepressive Agents
Disease-Free Survival
Inpatients
Coronary Artery Disease
Heart Diseases
Hospitalization
Cardiovascular Diseases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognosis of Patients Taking Selective Serotonin Reuptake Inhibitors Before Coronary Artery Bypass Grafting. / Xiong, Glen; Jiang, Wei; Clare, Robert; Shaw, Linda K.; Smith, Peter K.; Mahaffey, Kenneth W.; O'Connor, Christopher M.; Krishnan, K. Ranga R; Newby, L. Kristin.

In: American Journal of Cardiology, Vol. 98, No. 1, 01.07.2006, p. 42-47.

Research output: Contribution to journalArticle

Xiong, G, Jiang, W, Clare, R, Shaw, LK, Smith, PK, Mahaffey, KW, O'Connor, CM, Krishnan, KRR & Newby, LK 2006, 'Prognosis of Patients Taking Selective Serotonin Reuptake Inhibitors Before Coronary Artery Bypass Grafting', American Journal of Cardiology, vol. 98, no. 1, pp. 42-47. https://doi.org/10.1016/j.amjcard.2006.01.051
Xiong, Glen ; Jiang, Wei ; Clare, Robert ; Shaw, Linda K. ; Smith, Peter K. ; Mahaffey, Kenneth W. ; O'Connor, Christopher M. ; Krishnan, K. Ranga R ; Newby, L. Kristin. / Prognosis of Patients Taking Selective Serotonin Reuptake Inhibitors Before Coronary Artery Bypass Grafting. In: American Journal of Cardiology. 2006 ; Vol. 98, No. 1. pp. 42-47.
@article{65d461cee7f14785a3e177c26838ce0e,
title = "Prognosis of Patients Taking Selective Serotonin Reuptake Inhibitors Before Coronary Artery Bypass Grafting",
abstract = "Depression is increasingly recognized as an independent prognostic risk factor in patients with coronary artery disease and coronary artery bypass grafting (CABG). The use of selective serotonin reuptake inhibitors (SSRIs) for depression in patients with cardiac disease is becoming more prevalent. We examined the long-term outcomes of patients on SSRIs before CABG. We prospectively examined collected data in the Duke Databank for Cardiovascular Disease from January 1, 1999 to December 31, 2003. The median and maximum follow-up periods were 3 and 6 years, respectively. We screened patients who underwent CABG (n = 5,364) and excluded those who underwent simultaneous CABG and valvular surgery (n = 570). SSRI antidepressants included fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, and clomipramine, and their use was determined from the inpatient pharmacy records during the index hospitalization. Outcomes included event-free survival from all-cause mortality, rehospitalization, and a composite end point of all-cause mortality or rehospitalization. Of 4,794 CABG-only patients, 246 (5.1{\%}) took SSRIs before CABG. The SSRI group had a higher prevalence of diabetes, hypercholesterolemia, hypertension, cerebrovascular disease, peripheral vascular disease, and previous cardiovascular intervention. After adjustment for baseline differences, patients on SSRIs before CABG had increased risks of mortality, rehospitalization, and the composite end point (hazard ratio 1.61, 95{\%} confidence interval 1.17 to 2.21, p = 0.003; hazard ratio 1.52, 95{\%} confidence interval 1.30 to 1.77, p <0.0001; and hazard ratio 1.46, 95{\%} confidence interval 1.26 to 1.70, p <0.0001, respectively). In conclusion, SSRI use before CABG was associated with a higher risk of long-term post-CABG mortality and rehospitalization. The explanation behind these findings requires further research.",
author = "Glen Xiong and Wei Jiang and Robert Clare and Shaw, {Linda K.} and Smith, {Peter K.} and Mahaffey, {Kenneth W.} and O'Connor, {Christopher M.} and Krishnan, {K. Ranga R} and Newby, {L. Kristin}",
year = "2006",
month = "7",
day = "1",
doi = "10.1016/j.amjcard.2006.01.051",
language = "English (US)",
volume = "98",
pages = "42--47",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Prognosis of Patients Taking Selective Serotonin Reuptake Inhibitors Before Coronary Artery Bypass Grafting

AU - Xiong, Glen

AU - Jiang, Wei

AU - Clare, Robert

AU - Shaw, Linda K.

AU - Smith, Peter K.

AU - Mahaffey, Kenneth W.

AU - O'Connor, Christopher M.

AU - Krishnan, K. Ranga R

AU - Newby, L. Kristin

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Depression is increasingly recognized as an independent prognostic risk factor in patients with coronary artery disease and coronary artery bypass grafting (CABG). The use of selective serotonin reuptake inhibitors (SSRIs) for depression in patients with cardiac disease is becoming more prevalent. We examined the long-term outcomes of patients on SSRIs before CABG. We prospectively examined collected data in the Duke Databank for Cardiovascular Disease from January 1, 1999 to December 31, 2003. The median and maximum follow-up periods were 3 and 6 years, respectively. We screened patients who underwent CABG (n = 5,364) and excluded those who underwent simultaneous CABG and valvular surgery (n = 570). SSRI antidepressants included fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, and clomipramine, and their use was determined from the inpatient pharmacy records during the index hospitalization. Outcomes included event-free survival from all-cause mortality, rehospitalization, and a composite end point of all-cause mortality or rehospitalization. Of 4,794 CABG-only patients, 246 (5.1%) took SSRIs before CABG. The SSRI group had a higher prevalence of diabetes, hypercholesterolemia, hypertension, cerebrovascular disease, peripheral vascular disease, and previous cardiovascular intervention. After adjustment for baseline differences, patients on SSRIs before CABG had increased risks of mortality, rehospitalization, and the composite end point (hazard ratio 1.61, 95% confidence interval 1.17 to 2.21, p = 0.003; hazard ratio 1.52, 95% confidence interval 1.30 to 1.77, p <0.0001; and hazard ratio 1.46, 95% confidence interval 1.26 to 1.70, p <0.0001, respectively). In conclusion, SSRI use before CABG was associated with a higher risk of long-term post-CABG mortality and rehospitalization. The explanation behind these findings requires further research.

AB - Depression is increasingly recognized as an independent prognostic risk factor in patients with coronary artery disease and coronary artery bypass grafting (CABG). The use of selective serotonin reuptake inhibitors (SSRIs) for depression in patients with cardiac disease is becoming more prevalent. We examined the long-term outcomes of patients on SSRIs before CABG. We prospectively examined collected data in the Duke Databank for Cardiovascular Disease from January 1, 1999 to December 31, 2003. The median and maximum follow-up periods were 3 and 6 years, respectively. We screened patients who underwent CABG (n = 5,364) and excluded those who underwent simultaneous CABG and valvular surgery (n = 570). SSRI antidepressants included fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, and clomipramine, and their use was determined from the inpatient pharmacy records during the index hospitalization. Outcomes included event-free survival from all-cause mortality, rehospitalization, and a composite end point of all-cause mortality or rehospitalization. Of 4,794 CABG-only patients, 246 (5.1%) took SSRIs before CABG. The SSRI group had a higher prevalence of diabetes, hypercholesterolemia, hypertension, cerebrovascular disease, peripheral vascular disease, and previous cardiovascular intervention. After adjustment for baseline differences, patients on SSRIs before CABG had increased risks of mortality, rehospitalization, and the composite end point (hazard ratio 1.61, 95% confidence interval 1.17 to 2.21, p = 0.003; hazard ratio 1.52, 95% confidence interval 1.30 to 1.77, p <0.0001; and hazard ratio 1.46, 95% confidence interval 1.26 to 1.70, p <0.0001, respectively). In conclusion, SSRI use before CABG was associated with a higher risk of long-term post-CABG mortality and rehospitalization. The explanation behind these findings requires further research.

UR - http://www.scopus.com/inward/record.url?scp=33745155732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745155732&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2006.01.051

DO - 10.1016/j.amjcard.2006.01.051

M3 - Article

VL - 98

SP - 42

EP - 47

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -